DUBLIN–(BUSINESS WIRE)–The “Dysmenorrhea – Market Insight, Epidemiology and Market Forecast – 2030” drug pipelines has been added to ResearchAndMarkets.com’s providing.
This ‘Dysmenorrhea-Market Insights, Epidemiology and Market Forecast – 2030’ report delivers an in-depth understanding of the Dysmenorrhea, historic and forecasted epidemiology in addition to the Dysmenorrhea market tendencies within the United States, EU-5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.
The dysmenorrhea market report gives present remedy practices, rising medication, Dysmenorrhea market share of the person therapies, present and forecasted Dysmenorrhea market dimension from 2017 to 2030 segmented by seven main markets. The Report additionally covers present Dysmenorrhea remedy follow/algorithm, market drivers, market boundaries and unmet medical must curate better of the alternatives and assesses underlying potential of the market.
The Dysmenorrhea epidemiology division gives the insights about historic and present Dysmenorrhea affected person pool and forecasted development for every seven main nations. It helps to acknowledge the causes of present and forecasted tendencies by exploring quite a few research and views of key opinion leaders. This a part of The report additionally gives the recognized affected person pool and their tendencies together with assumptions undertaken.
The illness epidemiology lined within the report gives historic in addition to forecasted Dysmenorrhea epidemiology [segmented as Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea), Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea, Severity-specific Prevalent Cases of Primary dysmenorrhea, Severity-specific Prevalent Cases of Secondary dysmenorrhea, Treated cases of Primary and Secondary Dysmenorrhea] state of affairs of Dysmenorrhea within the 7MM masking the United States, EU5 nations (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.
Dysmenorrhea Emerging Drugs
Relugolix: Myovant Sciences GmbH/ Takeda
Myovant Sciences is growing its potential drug Relugolix, which is a small molecule consumed orally and its mechanism of motion contains performing as a GnRH receptor antagonist, for the remedy of uterine fibroids and endometriosis. Relugolix is essentially the most anticipated part III program for the remedy of endometriosis-related ache. For this candidate, Takeda has industrial rights for Japan together with some components of Asia. In different areas, Myovant Sciences holds commercialization rights. Myovant was fashioned by Takeda and Roivant Sciences in June 2016.
Yselty (Linzagolix; OBE2109): ObsEva
Yselty (beforehand often known as Linzagolixx, OBE2109) by ObsEva is a novel, oral, as soon as-each day, GnRH receptor antagonist with the tagline greatest-in-class profile. As per the corporate, the facet which makes it totally different from the opposite marketed GnRH, is that it has the potential to supply efficient administration of endometriosis-related ache whereas mitigating bone mineral density loss and different opposed results sometimes related to at present accepted remedies.
FSN-013 (Estetrol/ Drospirenone): Fuji Pharma
FSN-013 is a fifth technology mixed oral contraceptive drug of Fuji Pharma composed of estetrol (a pure estrogen) and drospirenone. As of now, it has exhibited a few of the eye-catching traits equivalent to improved bleeding management as in comparison with different medication. Along with this, it additionally has decrease lipid impression, and decrease interplay amongst different medication.
Pure Femme Tablets: Pure Green
Pure Green Pharmaceuticals is an rising the US-based mostly biotech begin-up, on the forefront of analysis into the therapeutic qualities of hashish. Currently, a part II (NCT04091789) scientific trial is in its recruiting stage which is anticipated to incorporate 30 sufferers.
Dysmenorrhea Market Outlook
Dysmenorrhea market within the 7MM is predicted to alter within the research interval 2017-2030.The therapeutic market of Dysmenorrhea in seven main markets was discovered to be USD 7,430 million in 2017 which is predicted to extend throughout research interval (2017-2030).
Key Topics Covered:
1. Key Insights
2. Executive Summary of Dysmenorrhea
3. SWOT Analysis
4. Epidemiology and Market Methodology
5. Dysmenorrhea: Market Share (%) Distribution Overview at a Glance: By Country
6. Dysmenorrhea: Disease Background and Overview
6.1. Types of Dysmenorrhea
6.2. Risk Factors
6.3. Signs and Symptoms
6.6. Diagnostic Algorithm
6.7. Diagnostic Guidelines
6.7.1. National Institute for Health and Care Excellence (NICE) Guidelines
7. Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale
7.3. Epidemiology Scenario: 7MM
8. Current Treatment Practices
8.1. Pharmacological Treatments
8.1.2. Hormonal contraception
8.1.3. Gonadotropin-releasing hormone (GnRH) analogs
8.2.1. Removal of the uterus (hysterectomy) and ovaries (oophorectomy)
8.2.2. Laparoscopic uterine nerve ablation and laparoscopic presacral neurectomy
8.3. Non-Pharmacological Treatments
8.3.1. Transcutaneous electrical nerve stimulation (TENS)
8.3.2. Supportive Therapies
8.4. Treatment Algorithms
8.5. Guideline of Dysmenorrhea
8.5.1. American College of Obstetricians and Gynecologists (ACOG) suggestions for Dysmenorrhea and Endometriosis within the Adolescent
8.5.2. NICE Recommendations: Endometriosis (2017)
8.5.3. Japan Society of Obstetrics and Gynecology (JSOG) and Japan Association of Obstetricians and Gynecologists (JAOG) 2017 version
8.5.4. Guideline of the European Society of Human Reproduction and Embryology (ESHRE) for Endometriosis-associated ache: 2013
9. Unmet Needs
10. Patient Journey
11. Key Endpoints in Dysmenorrhea Clinical Trials
12. Marketed Therapies
12.1. Marketed Key Cross
12.2. Orilissa (Elagolix): AbbVie/ Neurosciences Biosciences
12.2.1. Product Description
12.2.2. Regulatory Milestones
12.2.3. Other Developmental Activities
12.2.4. Pivotal Clinical Trial
12.2.5. Ongoing Clinical Trial Activity
12.3. Jemina Tablets (levonorgestrel – ethinylestradiol compound formulation): Nobelpharma/ASKA Pharmaceutical
12.4. Visanne (Dinagest): Mochida/Bayer Schering Pharma AG
13. Emerging Therapies
13.1. Yselty (Linzagolix; OBE2109): ObsEva
13.1.1. Product Description
13.1.2. Other Developmental Activities
13.1.3. Clinical Development
13.1.4. Safety and Efficacy
13.2. Relugolix (TAK-385): Myovant Sciences/Takeda
13.3. Pure Femme Tablets: Pure Green
13.4. FSN-013 (Estetrol/ Drospirenone): Fuji Pharma
13.5. NS-580: Nippon Shinyaku
14. Conjoint Analysis of Dysmenorrhea Therapies
15. Dysmenorrhea: Seven Major Market Analysis
15.1. Key Findings
15.2. Market Outlook
For extra details about this drug pipelines report go to https://www.researchandmarkets.com/r/pql54m